

PRESS RELEASE

2024.03.07



Cell4Cure becomes a member of Swedenbio

Solna, Sweden, 7 March 2024, Cell4Cure AB – a Swedish private ATMP company working with world leading antigen-specific dendritic cell mediated tolerance, aiming for curing disease where the immune system has become the enemy - today announced that they have joined the national trade organization for life sciences in Sweden, SwedenBIO. Cell4Cure has become a member of the non-profit membership organization, SwedenBIO, which is the Swedish trade organization for companies active within life science. SwedenBIO offers their member organizations direct access to an extensive network and knowledge within life science. They also constitute a strong voice in the debate. Christina Herder, CEO and co-founder: “As a member of SwedenBIO, we have direct access to a very valuable network within our area of life science. We will also benefit from their offers and discounts.”

For more information, please contact;
Christina Herder, co-founder and board member
Telephone: +46 703747156
E-mail: christina.herder@cell4cure.com

About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company's proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company's first clinical study, *Toler8*, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit www.cell4cure.com.